1349 Stock Overview
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.08 |
| 52 Week High | HK$3.29 |
| 52 Week Low | HK$2.03 |
| Beta | 0.31 |
| 1 Month Change | -7.96% |
| 3 Month Change | -9.57% |
| 1 Year Change | -36.39% |
| 3 Year Change | -57.02% |
| 5 Year Change | -69.28% |
| Change since IPO | 160.00% |
Recent News & Updates
Recent updates
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21Shareholder Returns
| 1349 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -2.3% | -4.5% | -2.0% |
| 1Y | -36.4% | -21.8% | -14.3% |
Return vs Industry: 1349 underperformed the Hong Kong Pharmaceuticals industry which returned -21.9% over the past year.
Return vs Market: 1349 underperformed the Hong Kong Market which returned -15% over the past year.
Price Volatility
| 1349 volatility | |
|---|---|
| 1349 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1349 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1349's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 948 | Da Jun Zhao | www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary
| 1349 fundamental statistics | |
|---|---|
| Market cap | HK$6.12b |
| Earnings (TTM) | HK$117.53m |
| Revenue (TTM) | HK$920.48m |
18.3x
P/E Ratio2.3x
P/S RatioIs 1349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1349 income statement (TTM) | |
|---|---|
| Revenue | CN¥850.73m |
| Cost of Revenue | CN¥74.08m |
| Gross Profit | CN¥776.66m |
| Other Expenses | CN¥668.03m |
| Earnings | CN¥108.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 91.29% |
| Net Profit Margin | 12.77% |
| Debt/Equity Ratio | 0% |
How did 1349 perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield67%
Payout RatioDoes 1349 pay a reliable dividends?
See 1349 dividend history and benchmarks| Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd dividend dates | |
|---|---|
| Ex Dividend Date | Jul 04 2024 |
| Dividend Pay Date | Aug 26 2024 |
| Days until Ex dividend | 75 days |
| Days until Dividend pay date | 128 days |
Does 1349 pay a reliable dividends?
See 1349 dividend history and benchmarks